Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Pediatric Hereditary Kidney Disease With Proteinuria
NCT06890143Phase 3Recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in hereditary kidney disease, sponsored by Children's Hospital of Fudan University. Started Mar 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
hereditary kidney disease
Beyond the preview
Go deeper on NCT06890143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890143.